Yüklüyor......
Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use
There is great heterogeneity in drug treatment response that is thought to be due to individual-level allelic variation in pharmacogenomic biomarkers. FDA Drug Labels provide information to guide pharmacogenomic biomarker use. Yet, the strength of evidence for clinical validity and clinical utility...
Kaydedildi:
| Yayımlandı: | AMIA Jt Summits Transl Sci Proc |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Medical Informatics Association
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5543369/ https://ncbi.nlm.nih.gov/pubmed/28815101 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|